Koga Arthur, Bani-Fatemi Ali, Hettige Nuwan, Borlido Carol, Zai Clement, Strauss John, Gerretsen Philip, Graff Ariel, Remington Gary, De Luca Vincenzo
EEG & Genetics Group, Centre for Addiction & Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
Pharmacogenomics. 2017 May;18(7):663-671. doi: 10.2217/pgs-2016-0137. Epub 2017 Apr 28.
In the current study, we aimed to compare the prevalence of adverse lifetime events in treatment resistant and non-treatment resistant schizophrenia in a genome-wide association study.
MATERIALS & METHODS: Our sample consisted of 84 Caucasian participants with schizophrenia spectrum disorders, assessed cross-sectionally to collect information regarding drug effectiveness and childhood trauma. Using a genome-wide association analysis, we tested single-nucleotide polymorphisms for their association with resistance to antipsychotics defined according to American Psychiatric Association criteria. Two models were tested: a main model and an interaction model with the childhood trauma.
Our analysis failed to demonstrate a significant relationship among 1,178,234 single-nucleotide polymorphisms and treatment-resistance in both the main model and in the childhood trauma interaction model.
Even though we could not find any significant association, treatment resistance has clinical relevance and it may be determined by the interaction between biological and non biological factors.
在本研究中，我们旨在通过全基因组关联研究比较难治性和非难治性精神分裂症患者一生中不良事件的发生率。
我们的样本包括84名患有精神分裂症谱系障碍的白种人参与者，通过横断面评估收集有关药物疗效和童年创伤的信息。使用全基因组关联分析，我们测试了单核苷酸多态性与根据美国精神病学协会标准定义的抗精神病药物耐药性之间的关联。测试了两种模型：主模型和与童年创伤的交互模型。
我们的分析未能在主模型和童年创伤交互模型中证明1,178,234个单核苷酸多态性与治疗耐药性之间存在显著关系。
尽管我们未发现任何显著关联，但治疗耐药性具有临床相关性，可能由生物学和非生物学因素之间的相互作用决定。
